Tysabri and PML: Recognizing Early Warning Signs in Florida Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specialized Legal Guidance

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, it's important to know the warning signs of progressive multifocal leukoencephalopathy (PML). The long-standing tradition of patient education and medical transparency has helped many individuals recognize serious side effects early. This guide provides an overview of PML symptoms, monitoring protocols, and what Florida patients should consider.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs almost exclusively in immunocompromised individuals, and Tysabri’s mechanism—blocking lymphocyte migration into the central nervous system—can create a permissive environment for JCV reactivation. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes subacute neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white-matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) data for Tysabri list fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, balance disorder, and cognitive disorder among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis itself, any new or worsening neurological signs should prompt immediate evaluation for PML.

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its binding to alpha-4 integrin on lymphocytes, preventing their adhesion to endothelial cells and subsequent migration into the brain. This reduces immune surveillance in the central nervous system, allowing latent JCV to reactivate and infect oligodendrocytes, leading to demyelination and neuronal damage. The risk is highest in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have previously used immunosuppressive therapies such as mitoxantrone, cyclophosphamide, or azathioprine. For patients in Florida who have developed PML after Tysabri exposure, legal considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury actions is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given that PML can manifest months to years after starting Tysabri, the timeline between exposure and documented harm is critical. Patients or their families should consult with an attorney experienced in pharmaceutical litigation to determine whether their claim falls within the applicable filing window.

Adequacy of Warnings and Legal Considerations

Adequacy of warnings is a central issue in such cases. The Tysabri label includes a boxed warning and detailed precautions about PML risk, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the specific risk factors, and the importance of early monitoring. The label states that the three risk factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, if a patient was not tested for anti-JCV antibodies before or during therapy, or if the significance of treatment duration was not clearly communicated, the warning may be deemed insufficient. Attorney-related considerations for affected patients include gathering medical records documenting Tysabri administration dates, anti-JCV antibody test results, MRI findings, and PML diagnosis. Expert testimony from neurologists and infectious disease specialists may be needed to establish causation and the standard of care. The timeline between exposure and harm is often documented through infusion records and clinical notes showing the onset of neurological symptoms. In Florida, the discovery rule may extend the statute of limitations if the injury was not immediately apparent, but prompt legal consultation is advisable.

Summary and Next Steps

In summary, Tysabri-associated PML is a serious, often devastating complication with well-defined risk factors. Patients in Florida who have suffered PML should be aware of the statute of limitations and seek legal advice to evaluate their options. The adequacy of warnings and the timing of diagnosis are key factors in any potential claim. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Florida?

In Florida, the statute of limitations for personal injury actions is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given that PML can manifest months to years after starting Tysabri, it is crucial to consult an attorney promptly to determine if your claim falls within the applicable window.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants such as mitoxantrone, cyclophosphamide, or azathioprine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.